Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Cabazitaxel
EFC11785
NCT01308580
EudraCT2010-022163-35
Prostatic Neoplasm, Prostate Cancer
Phase 3
 
Datasets and document are available as per Sanofi Policy and criteria
August 2017

Powered by ideaPoint, Inc.